Hepatitis C virus NS5A inhibitors and drug resistance mutations

doi:10.3748/wjg.v20.i11.2902

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 20, Issue 11

This Article

Academic Content and Language Evaluation of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (10746)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-3) series, Tables (1-2) series.

Item

Count

PDF

1029

WORD

391

HTML

6858

Figures (1-3)

280

Tables (1-2)

193

Sum=8751

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1030

Download

964

Sum=1994

Mar 21, 2014 (publication date) through Nov 19, 2024

Times Cited of This Article

Times Cited (107)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Topic Highlight

World J Gastroenterol. Mar 21, 2014; 20(11): 2902-2912
Published online Mar 21, 2014. doi: 10.3748/wjg.v20.i11.2902

Table 1 In vitro resistance profiles according to hepatitis C virus genotypes[36,40,50-54,64]

EC₅₀	< 10 pmol/L	< 100 pmol/L	< 1 nmol/L	< 10 nmol/L	< 100 nmol/L	< 1 μmol/L	> 1 μmol/L
DCV
HCV GT
1b	Wild (2.6 pmol/L)	R30E, H	23F/93H		31F, M, V/93H		Δ30/32L
	L28M	L31F, V	30Q/31F		30Q/31M/93H
	L31M	P32L	31V/58S
	R30Q	Y93H, N	30H/31M
		37L or 54H/93H
		23F/31F
1a	Wild (6 pmol/L)			M28T	L31V	Q30E, K	31V/93H
				Q30H, R	Y93C, H	Y93N (> 500 nmol/L)
				L31M		28T/30H
				P32L		30H/93H
				H58D		30R/93C
						30R/62D
2-6		GT2a (JFH1)	GT3a	GT2a (L31M)	GT2a (Y93H)	GT2a (F28S)
		GT4a, 5a, 6a		GT2a (C92R)	GT2b (31M)	GT3a (Y93H)
					GT3a (A30K)	GT4a (L30I/Y93R)
					GT3a (L31F)
					GT4a (R30G)
					GT4a (L30H)
ACH-3102
HCV GT
1b	Wild (7 pmol/L)	Y93H	P58S/Y93H
	L31V	31V/93H	P58S/T64A/Y93H

1a		wild (20 pmol/L)	Q30R, E, K	Y93C	Y93H, N¹
		Q30H	M28T		28T/30H/93C¹
		L31M, V	P32L
			H58D

2-6			GT2a (JFH1)
			GT2a (L31M)
			GT2b (31M)
			GT3a, 4a, 5a, 6a

¹Analysis of hepatitis C virus (HCV) NS5A from patient samples[75]. EC₅₀: Half maximal (50%) effective concentration; DCV: Daclatasvir; GT: Genotype.

Citation: Nakamoto S, Kanda T, Wu S, Shirasawa H, Yokosuka O. Hepatitis C virus NS5A inhibitors and drug resistance mutations. World J Gastroenterol 2014; 20(11): 2902-2912
URL: https://www.wjgnet.com/1007-9327/full/v20/i11/2902.htm
DOI: https://dx.doi.org/10.3748/wjg.v20.i11.2902